Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD

Gene Therapy

Volumn 19, Issue 4, 2012, Pages 453-457

  Rojas, J J ^a   Gimenez Alejandre, M ^a   Gil Hoyos, R ^a   Cascallo, M ^a   Alemany, R ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

antitumor efficacy; fiber shaft; HSG binding domain; oncolytic adenovirus; RGD motif

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGINYLGLYCYLASPARTIC ACID; ASPARTATE AMINOTRANSFERASE; E1A PROTEIN; HEPARAN SULFATE; ONCOLYTIC ADENOVIRUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BINDING SITE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER; LYMPHOCYTOPENIA; MALE; MELANOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THROMBOCYTOPENIA; WILD TYPE;

ADENOVIRIDAE; ANIMALS; BINDING SITES; CELL LINE, TUMOR; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPARITIN SULFATE; MICE; MICE, INBRED BALB C; NEOPLASMS; OLIGOPEPTIDES; ONCOLYTIC VIROTHERAPY; RECEPTORS, CELL SURFACE;

ADENOVIRIDAE; MUS;

EID: 84859611033     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.106     Document Type: Article

References (21)

1. Di Paolo NC, Shayakhmetov DM. Adenovirus de-targeting from the liver. Curr Opin Mol Ther 2009; 11: 523-531.
2. Bayo-Puxan N, Cascallo M, Gros A, Huch M, Fillat C, Alemany R. Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol 2006; 87: 2487-2495.
3. Martin K, Brie A, Saulnier P, Perricaudet M, Yeh P, Vigne E. Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther 2003; 8: 485-494. (Pubitemid 37161470)
4. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, Stewart PL et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. ProcNatl Acad Sci USA 2008; 105: 5483-5488. (Pubitemid 351753889)
5. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409. (Pubitemid 351200513)
6. Gimenez-Alejandre M, Cascallo M, Bayo-Puxan N, Alemany R. Coagulation factors determine tumor transduction in vivo. Hum Gene Ther 2008; 19: 1415-1419.
7. Kritz AB, Nicol CG, Dishart KL, Nelson R, Holbeck S, Von Seggern DJ et al. Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. Mol Ther 2007; 15: 741-749. (Pubitemid 46431994)
8. Rittner K, Schreiber V, Erbs P, Lusky M. Targeting of adenovirus vectors carrying a tumor cell-specific peptide: in vitro and in vivo studies. Cancer Gene Ther 2007; 14: 509-518. (Pubitemid 46588195)
9. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998; 72: 1844-1852. (Pubitemid 28100735)
10. Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 2002; 76: 8621-8631. (Pubitemid 34864056)
11. Xia H, Anderson B, Mao Q, Davidson BL. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol 2000; 74: 11359-11366. (Pubitemid 32224006)
12. Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266-1270. (Pubitemid 34407775)
13. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713. (Pubitemid 28520834)
14. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7: 120-126. (Pubitemid 32110214)
15. Bayo-Puxan N, Gimenez-Alejandre M, Lavilla-Alonso S, Gros A, Cascallo M, Hemminki A et al. Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum Gene Ther 2009; 20: 1214-1221.
16. Rojas JJ, Guedan S, Searle PF, Martinez-Quintanilla J, Gil-Hoyos R, Alcayaga-Miranda F et al. Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-arming Capacity in Oncolytic Adenoviruses. Mol Ther 2010; 18: 1960-1971.
17. Aghi M, Martuza RL. Oncolytic viral therapies-the clinical experience. Oncogene 2005; 24: 7802-7816. (Pubitemid 41670681)
18. Liu Q, Zaiss AK, Colarusso P, Patel K, Haljan G, Wickham TJ et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 2003; 14: 627-643. (Pubitemid 36543435)
19. Cascallo M, Alonso MM, Rojas JJ, Perez-Gimenez A, Fueyo J, Alemany R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther 2007; 15: 1607-1615. (Pubitemid 47296599)
20. Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 1998; 17: 1969-1978. (Pubitemid 28488465)
21. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010; 18: 1275-1283.